Literature DB >> 19363439

Intestinal differentiation in metaplastic, nongoblet columnar epithelium in the esophagus.

Hejin P Hahn1, Patricia L Blount, Kamrun Ayub, Kiron M Das, Rhonda Souza, Stuart Spechler, Robert D Odze.   

Abstract

Barrett esophagus (BE) is defined by the presence of metaplastic esophageal columnar epithelium with goblet cells within endoscopically recognizable areas of the esophagus. However, some carcinomas in BE, or from the gastroesophageal junction region, develop within mucosa devoid of goblet cells. However, the biologic properties, pathogenesis, and risk of malignancy of metaplastic, esophageal nongoblet columnar epithelium, is, essentially, unknown. In this study, 89 patients with metaplastic esophageal columnar epithelium were evaluated immunohistochemically for markers of intestinal differentiation, such as MUC2, DAS-1, Villin, and CDX2, a marker of gastric differentiation (MUC5AC), and Ki67, a marker of cell proliferation. Of the 89 patients, 59 had columnar metaplasia with goblet cells (BE), which were further separated into low-density goblet cell and high-density goblet cell groups based on the percentage of crypts with goblet cells, and 30 patients had columnar metaplasia of the esophagus without goblet cells. As controls, gastric biopsies from 19 age and sex matched patients without esophageal or gastric pathology were used. The rate of positivity of the markers and the location of Ki67 staining was evaluated only in non-goblet columnar epithelium from all patient groups. Patients with metaplastic esophageal columnar epithelium without goblet cells showed positivity for MUC5AC, MUC2, DAS-1, Villin, and CDX2 in 100%, 0%, 30%, 17%, and 43% of cases, respectively. 17% of cases showed aberrant surface Ki67 positivity. These values were significantly higher than gastric controls, which showed absence of staining for all markers except MUC5AC (100%). In patients with metaplastic esophageal columnar epithelium with goblet cells (BE) a significant increased rate of staining was observed for all markers, except MUC5AC. In addition, both MUC2 and surface Ki67 staining were significantly increased in BE patients with high-density goblet cells versus those with low-density goblet cells. In a separate analysis in which metaplastic esophageal nongoblet epithelium was evaluated in areas of mucosa devoid of goblet cells compared with areas of mucosa with goblet cells, from patients who had goblet cells elsewhere in the mucosa (N=59), no significant differences were observed with regard to the percentage of cases that stained with any of the markers in the nongoblet epithelium in areas devoid of goblet cells, similar to the patient group with metaplastic esophageal epithelium without goblet cells (N=30). Similar to above, in all cases, expression of intestinal markers increased in areas of mucosa adjacent to goblet cells. This study provides evidence that metaplastic esophageal columnar epithelium without goblet cells shows phenotypic evidence of intestinal differentiation and supports the theory that squamous epithelium converts initially to nongoblet columnar epithelium before goblet cell metaplasia. Further prospective studies are needed to evaluate the pathogenetic sequence, natural history, and risk of malignancy of metaplastic esophageal nongoblet epithelium.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363439      PMCID: PMC2807916          DOI: 10.1097/PAS.0b013e31819f57e9

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  42 in total

1.  Gastric and intestinal differentiation in Barrett's metaplasia and associated adenocarcinoma.

Authors:  P Chaves; C Cruz; A Dias Pereira; A Suspiro; J C M de Almeida; C N Leitão; J Soares
Journal:  Dis Esophagus       Date:  2005       Impact factor: 3.429

2.  Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.

Authors:  Kenneth K Wang; Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2008-03       Impact factor: 10.864

3.  Immunohistochemical study of MUC5AC expression in human gastric carcinomas using a novel monoclonal antibody.

Authors:  C A Reis; L David; P A Nielsen; H Clausen; K Mirgorodskaya; P Roepstorff; M Sobrinho-Simões
Journal:  Int J Cancer       Date:  1997-02-20       Impact factor: 7.396

4.  Molecular alterations of Barrett's esophagus on microdissected endoscopic biopsies.

Authors:  S Romagnoli; M Roncalli; D Graziani; B Cassani; E Roz; L Bonavina; A Peracchia; S Bosari; G Coggi
Journal:  Lab Invest       Date:  2001-02       Impact factor: 5.662

Review 5.  Concepts in the prevention of adenocarcinoma of the distal esophagus and proximal stomach.

Authors:  Rhonda F Souza; Stuart J Spechler
Journal:  CA Cancer J Clin       Date:  2005 Nov-Dec       Impact factor: 508.702

6.  Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study.

Authors:  Dennis L Chao; Carissa A Sanchez; Patricia C Galipeau; Patricia L Blount; Thomas G Paulson; David S Cowan; Kamran Ayub; Robert D Odze; Peter S Rabinovitch; Brian J Reid
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

7.  Cdx2 as a marker of epithelial intestinal differentiation in the esophagus.

Authors:  Roy W Phillips; Henry F Frierson; Christopher A Moskaluk
Journal:  Am J Surg Pathol       Date:  2003-11       Impact factor: 6.394

8.  Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus.

Authors:  Piers A C Gatenby; James R Ramus; Christine P J Caygill; Neil A Shepherd; Anthony Watson
Journal:  Scand J Gastroenterol       Date:  2008       Impact factor: 2.423

9.  Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections.

Authors:  G Cattoretti; M H Becker; G Key; M Duchrow; C Schlüter; J Galle; J Gerdes
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

10.  Hepatocyte antigen as a marker of intestinal metaplasia.

Authors:  Peiguo G Chu; Zhong Jiang; Lawrence M Weiss
Journal:  Am J Surg Pathol       Date:  2003-07       Impact factor: 6.394

View more
  57 in total

1.  Activation of the BMP4 pathway and early expression of CDX2 characterize non-specialized columnar metaplasia in a human model of Barrett's esophagus.

Authors:  Daniel Castillo; Sonia Puig; Mar Iglesias; Agustín Seoane; Carme de Bolós; Vicente Munitiz; Pascual Parrilla; Laura Comerma; Richard Poulsom; Kausilia K Krishnadath; Luís Grande; Manuel Pera
Journal:  J Gastrointest Surg       Date:  2011-11-11       Impact factor: 3.452

Review 2.  [Barrett's esophagus. An update].

Authors:  G B Baretton; D E Aust
Journal:  Pathologe       Date:  2012-02       Impact factor: 1.011

Review 3.  Barrett's esophagus: Clinical issues.

Authors:  Stuart Jon Spechler
Journal:  Gastrointest Endosc Clin N Am       Date:  2011-01

Review 4.  Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.

Authors:  Bita V Naini; Rhonda F Souza; Robert D Odze
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

Review 5.  [Update on Barrett esophagus and Barrett carcinoma].

Authors:  M Werner; S Laßmann
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

Review 6.  Barrett esophagus: histology and pathology for the clinician.

Authors:  Robert D Odze
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

Review 7.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 8.  Barrett oesophagus: lessons on its origins from the lesion itself.

Authors:  Stuart A C McDonald; Danielle Lavery; Nicholas A Wright; Marnix Jansen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-04       Impact factor: 46.802

Review 9.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

10.  Barrett's esophagus: is the goblet half empty?

Authors:  Stuart Jon Spechler
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-17       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.